Subarachnoid Hemorrhage – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Subarachnoid Hemorrhage – Drugs In Development, 2024 report and make more profitable business decisions.
Subarachnoid hemorrhage refers to the occurrence of bleeding within the subarachnoid space, the region between the brain and its delicate covering tissues. This condition demands immediate medical intervention due to its emergent nature. Causes encompass diverse factors, including arteriovenous malformations (AVMs), bleeding disorders, cerebral aneurysms, head injuries, and the use of blood thinners. The hallmark symptom is a sudden and severe headache, often described as a “thunderclap headache,” with notable intensity at the back of the head. Treatment objectives focus on preserving life, addressing the underlying cause, alleviating symptoms, and preventing complications like permanent brain damage. Surgical interventions may be necessary to evacuate blood collections, relieve pressure, or repair ruptured aneurysms associated with the hemorrhage.
The Subarachnoid Hemorrhage drugs in development market research report provide comprehensive information on the therapeutics under development for Subarachnoid Hemorrhage, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Subarachnoid Hemorrhage and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Subarachnoid Hemorrhage | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 21 molecules, with 21 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Subarachnoid Hemorrhage therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Subarachnoid Hemorrhage pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Subarachnoid Hemorrhage treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
Acasti Pharma IncAlexion Pharmaceuticals Inc
Aneuryst Inc
BIT Pharma GmbH
Cenyx Biotech Inc
Cipla Ltd
CSL Ltd
Edvince AB
F. Hoffmann-La Roche Ltd
ImmunoChem Therapeutics LLC
Loxagen Inc
NeurOp Inc
NeuroTrauma Sciences LLC
Neuvarx LLC
NoNO Inc
Orion Corp
Qanatpharma GmbH
Resolve Therapeutics LLC
Simcere Pharmaceutical Group Ltd
Takeda Pharmaceutical Co Ltd
Worphmed Srl
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Subarachnoid Hemorrhage reports